On June 27th, the Minister of Health of Laos, Bunphon Boumalai, met with a delegation of visiting Chinese pharmaceutical companies in Vientiane, the capital of Vientiane, at which Mr. Wang Bo, the founder of the Pharmaceutical Finance Circle, put forward many pertinent suggestions to the Lao Ministry of Health for the development of the pharmaceutical industry, and the two sides conducted in-depth and fruitful exchanges on a series of key issues, including the cooperation mechanism of Chinese pharmaceutical companies in Laos investment/factory/drug trade, cooperation between China and Laos in the cultivation of traditional Chinese medicines, plant extraction, and trade in medicinal materials. A number of cooperation consensuses have been reached on biopharmaceutical cooperation.
The delegation of Chinese pharmaceutical companies was carefully planned by the Pharmaceutical Finance Circle, with the collaborative support of lawyers Luo Zhengyu and Fan Yongjie of Laos Weizhen Law Firm and Guangdong Yinglong Law Firm, bringing together senior decision-makers from Livzon Pharmaceutical, Xintiandi Pharmaceutical, Yikang Pharmaceutical and other companies in China's domestic pharmaceutical industry. Through in-depth exchanges with the Minister of Health of Laos, Bunphon Phumalai, on the basis of a number of cooperation consensuses, the two sides have consolidated the foundation of cooperation and strengthened the mechanism of regular exchanges and dialogues. This visit is not only an important step for Chinese pharmaceutical companies to enter the ASEAN market, but also a useful exploration of the international pharmaceutical industry cooperation model.
Wang Bo, founder of the Pharmaceutical Finance Circle (left) Bounfenh, Minister of Health of Laos (right)
The Ministry of Health of Laos attaches great importance to the visit of the Chinese business delegation. Mr. Bounfenh, Minister of Health of Laos, Ms. Aphon Khaanthep, Director of the General Staff of the Ministry of Health, Mr. Bounsu Keo Havong, Director of the Department of Food and Drug Control, Dr. Chandali, Deputy Director General of the Ministry of Foreign Affairs, Mr. Boon Loong Duangmuk, Director of the Institute of Medicine and Traditional Medicine, Dr. Phong Savang, Secretary of the Ministry of Health, and Mr. Chen Xiang, General Manager of Wanda Vista Vientiane, demonstrating Laos' firm determination to strengthen China-Laos medical cooperation.
As an important member of ASEAN countries and the rotating chair of ASEAN in 2024, Laos is actively playing a key role in promoting ASEAN-China cooperation. In the field of medicine, the cooperation between Laos and China has maintained a strong growth momentum, and Laos' chemical technology has been continuously improved with the support of China, which has won more competitive advantages for both parties in the international pharmaceutical market.
During the field visit, the delegation learned that Laos, as a generic drug country, has relatively relaxed pharmaceutical policies. In terms of drug variety declaration, the declaration cost is relatively low, and the time cycle is only about three months, which provides a good opportunity for Chinese pharmaceutical companies to change their thinking, adjust their strategies, and lay out the Southeast Asian market.
We hope to lead more Chinese pharmaceutical companies to go abroad, actively integrate into the global pharmaceutical R&D and manufacturing market, embrace the stars of the pharmaceutical industry, and contribute "Chinese strength" to the healthy development of the global pharmaceutical industry.
Up to now, the pharmaceutical finance circle has covered 25,000 pharmaceutical companies in China, with more than 20,000 Chinese pharmaceutical companies chairman/general manager and other high-end network resources, the visit of the Chinese pharmaceutical delegation to Laos, the two sides on the cooperation of Chinese pharmaceutical enterprises in Laos investment/factory establishment/joint development/drug application and approval, etc., to have a candid, pragmatic, efficient and fruitful discussion, laying a solid foundation for the next step of cooperation between Chinese enterprises in Laos.
It is reported that from September to October this year, the pharmaceutical finance circle will organize more than 30 Chinese enterprises to form a huge delegation of Chinese pharmaceutical companies to visit Laos again to conduct an in-depth investigation of the pharmaceutical industry and policy status of Laos and ASEAN countries, implement the strategic layout of the internationalization of Chinese pharmaceutical enterprises, and open a new chapter for Chinese pharmaceutical companies to the world.
This Chinese pharmaceutical company delegation enterprises
Livzon Group
Founded in January 1985, Livzon Pharmaceutical Group Co., Ltd. is a comprehensive pharmaceutical group company integrating R&D, production and sales of pharmaceutical products, and an A+H share listed company. In 2023, the company's operating income will be 12.43 billion yuan, net profit will be 1.954 billion yuan, and R&D investment will be 1.235 billion yuan, accounting for 9.94% of operating income.
The company regards R&D and innovation as the cornerstone of sustainable development, continues to pay attention to new molecules and cutting-edge technologies in the field of global new drug R&D, and lays out innovative drugs and high-barrier complex preparations based on clinical value and differentiation, focusing on the fields of digestive tract, assisted reproduction, psychiatry, tumor immunity, etc., forming a complete product cluster and a differentiated product pipeline covering the whole cycle of R&D.
In the future, Livzon will continue to adhere to the mission of "quality of life of patients first" and the vision of "being a leader in the pharmaceutical industry", focus on the field of life and health, continue to be guided by the clinical needs of patients, accelerate the improvement of R&D efficiency through digital and intelligent technology models, further strengthen its leading edge in the platform of innovative drugs and complex preparations with high barriers, and comprehensively improve its sustainable development capabilities. At the same time, we will actively respond to the call of national policies, continue to shoulder the responsibility of pharmaceutical companies, and make more contributions to a healthy China.
Xintiandi Pharmaceutical
Xintiandi Pharmaceutical Co., Ltd. is located in Changge Economic and Technological Development Zone, Henan Province, and was established in 2005. Mainly engaged in the research and development, production and sales of pharmaceutical intermediates and APIs, it is an important manufacturer of L-hydroxyphenylglycine in the world's important amoxicillin synthetic side chain, and has led or participated in the formulation of industry standards for many products such as L-p-hydroxyphenylglycine, p-toluenesulfonic acid and L-p-hydroxyphenylglycine methyl ester, and is the second batch of specialized and special new enterprises in Henan Province.
The company has a number of core technology invention patents, one of which has been authorized by 8 countries such as the United States, Britain, Japan and India. In the second half of 2019, the company ranked first in the pharmaceutical industry in the green development research and evaluation of 17 industries in Henan Province; In 2020, the company held an on-site observation meeting on dual prevention in Henan Province; In 2021, the company obtained an A-level rating for the performance of key industries in heavily polluted weather.
The company has successively won many honors and qualifications such as Henan Province Specialized and Special New Enterprise, Henan Province Technology Innovation Demonstration Enterprise, Henan Province Energy Conservation and Emission Reduction Technology Innovation Demonstration Enterprise, Henan Province Intellectual Property Demonstration Enterprise and so on.
Yikang Pharmaceutical
Shandong Yikang Pharmaceutical Co., Ltd. was established in January 1999 and is a core subsidiary of Yikang Group. Yikang Pharmaceutical wholly-owned Shandong Kanghong Chemical Co., Ltd., Elaline (Shandong) Biomedical Technology Co., Ltd., Yinuo (Hainan) Pharmaceutical Co., Ltd., and Shandong Kanghu Medical Technology Co., Ltd. At present, there are more than 80 varieties of cephalosporins, penicillins, hypoglycemic drugs, digestive system, respiratory system, tumor adjuvant drugs, etc. The industrial chain is complete, the product categories are complete, and the new GMP certification has passed. Yikang Pharmaceutical Co., Ltd. is a national high-tech enterprise, one of the first batch of specialized and new "little giant" enterprises of the Ministry of Industry and Information Technology, a gazelle enterprise in Shandong Province, a patent star enterprise in Shandong Province, a leading enterprise in the medical care and health industry in Shandong Province, the first batch of Taishan scholars to set up posts, and the main enterprise of the new pharmaceutical industry chain in Zaozhuang City.